{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:45:36Z","timestamp":1790109936803,"version":"4.0.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1038\/ncpendmet0160","type":"journal-article","created":{"date-parts":[[2006,5,16]],"date-time":"2006-05-16T16:37:57Z","timestamp":1147797477000},"page":"200-210","source":"Crossref","is-referenced-by-count":55,"title":["Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women"],"prefix":"10.1038","volume":"2","author":[{"given":"Annamaria","family":"Colao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Di Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermelinda","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mentone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpendmet0160_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","volume":"41","author":"T Mindermann","year":"1994","unstructured":"Mindermann T and Wilson CH (1994) Age-related and gender-related occurrence of pituitary tumors. Clin Endocrinol 41: 359\u2013364","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0160_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3171\/jns.1994.80.2.0209","volume":"80","author":"MD Partington","year":"1994","unstructured":"Partington MD  et al. (1994) Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J Neurosurg 80: 209\u2013216","journal-title":"J Neurosurg"},{"key":"BFncpendmet0160_CR3","volume-title":"Pediatric Endocrinology","author":"A Colao","year":"2003","unstructured":"Colao A (2003) Pituitary tumors in childhood. In Pediatric Endocrinology, chapter 3 (Ed. New MI) Endotext.com [\n                    http:\/\/www.endotext.org\/pediatrics\/pediatrics3\/pediatricsframe3.htm\n                    \n                  ] (accessed 20 January 2006)"},{"key":"BFncpendmet0160_CR4","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S0140-6736(98)03356-X","volume":"352","author":"A Colao","year":"1998","unstructured":"Colao A and Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352: 1455\u20131461","journal-title":"Lancet"},{"key":"BFncpendmet0160_CR5","unstructured":"Beckers A  et al. Approaching the true prevalence of pituitary tumors. ENEA (The European Neuroendocrine Association) Meeting (NA): 2004 24\u201327 April; Sorrento, Italy, 23, [Abstract #1.1]"},{"key":"BFncpendmet0160_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao A  et al. (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148: 325\u2013331","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0160_CR7","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1001\/jama.1980.03310230014010","volume":"244","author":"B Ambrosi","year":"1980","unstructured":"Ambrosi B  et al. (1980) Prolactin and sexual function. JAMA 244: 2608","journal-title":"JAMA"},{"key":"BFncpendmet0160_CR8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJM197810192991602","volume":"299","author":"JN Carter","year":"1978","unstructured":"Carter JN  et al. (1978) Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 299: 847\u2013852","journal-title":"N Engl J Med"},{"key":"BFncpendmet0160_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.7326\/0003-4819-100-1-115","volume":"100","author":"MC Koppelman","year":"1984","unstructured":"Koppelman MC  et al. (1984) Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases. Ann Intern Med 100: 115\u2013121","journal-title":"Ann Intern Med"},{"key":"BFncpendmet0160_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0002-9378(81)90553-6","volume":"139","author":"CM March","year":"1981","unstructured":"March CM  et al. (1981) Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139: 835\u2013844","journal-title":"Am J Obstet Gynecol"},{"key":"BFncpendmet0160_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1210\/jcem-68-2-412","volume":"68","author":"J Schlechte","year":"1989","unstructured":"Schlechte J  et al. (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68: 412\u2013418","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0015-0282(16)59292-9","volume":"48","author":"DA Sisam","year":"1987","unstructured":"Sisam DA  et al. (1987) The natural history of untreated microprolactinomas. Fertil Steril 48: 67\u201371","journal-title":"Fertil Steril"},{"key":"BFncpendmet0160_CR13","first-page":"175","volume":"584","author":"K Von Werder","year":"1982","unstructured":"Von Werder K  et al. (1982) Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment. Excerpta Med Int Congr Ser 584: 175\u2013188","journal-title":"Excerpta Med Int Congr Ser"},{"key":"BFncpendmet0160_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1227\/00006123-198302000-00008","volume":"12","author":"MH Weiss","year":"1983","unstructured":"Weiss MH  et al. (1983) Natural history of microprolactinomas: six-year follow-up. Neurosurgery 12: 180\u2013183","journal-title":"Neurosurgery"},{"key":"BFncpendmet0160_CR15","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1210\/jcem.82.4.3845","volume":"82","author":"ME Molitch","year":"1997","unstructured":"Molitch ME  et al. (1997) Management of prolactinomas. J Clin Endocrinol Metab 82: 996\u20131000","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","volume":"100","author":"ML Vance","year":"1984","unstructured":"Vance ML  et al. (1984) Bromocriptine. Ann Intern Med 100: 78\u201391","journal-title":"Ann Intern Med"},{"key":"BFncpendmet0160_CR17","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"Molitch ME  et al. (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60: 698\u2013705","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/edrv-13-2-220","volume":"13","author":"JS Bevan","year":"1992","unstructured":"Bevan JS  et al. (1992) Dopamine agonists and pituitary tumour shrinkage. Endocr Rev 13: 220\u2013240","journal-title":"Endocr Rev"},{"key":"BFncpendmet0160_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J  et al. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. N Engl J Med 331: 904\u2013909","journal-title":"N Engl J Med"},{"key":"BFncpendmet0160_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","volume":"46","author":"CI Ferrari","year":"1997","unstructured":"Ferrari CI  et al. (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 46: 409\u2013413","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0160_CR21","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J  et al. (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84: 2518\u20132522","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR22","first-page":"2247","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A  et al. (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85: 2247\u20132252","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR23","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A  et al. (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. J Clin Endocrinol Metab 86: 5256\u20135261","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1056\/NEJM198509123131103","volume":"313","author":"A Liuzzi","year":"1985","unstructured":"Liuzzi A  et al. (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313: 656\u2013659","journal-title":"N Engl J Med"},{"key":"BFncpendmet0160_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1507\/endocrj.42.153","volume":"42","author":"K Eguchi","year":"1995","unstructured":"Eguchi K  et al. (1995) In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocr J 42: 153\u2013161","journal-title":"Endocr J"},{"key":"BFncpendmet0160_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1507\/endocrj.42.413","volume":"42","author":"K Eguchi","year":"1995","unstructured":"Eguchi K  et al. (1995) Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies. Endocr J 42: 413\u2013420","journal-title":"Endocr J"},{"key":"BFncpendmet0160_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2125.1987.tb03072.x","volume":"23","author":"AE Pontiroli","year":"1987","unstructured":"Pontiroli AE  et al. (1987) Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3\u2032-dimethylaminopropyl)-3-(6\u2032 allylergoline-8\u2032-\u03b2-carbonyl)urea-diphosphate (fce 21336). Br J Clin Pharmacol 23: 433\u2013438","journal-title":"Br J Clin Pharmacol"},{"key":"BFncpendmet0160_CR28","first-page":"841","volume":"80","author":"AC Andreotti","year":"1995","unstructured":"Andreotti AC  et al. (1995) Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab 80: 841\u2013845","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1210\/jcem-65-3-541","volume":"65","author":"GB Melis","year":"1987","unstructured":"Melis GB  et al. (1987) Dose related prolactin-inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women. J Clin Endocrinol Metab 65: 541\u2013545","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR30","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/0002-9343(83)90418-7","volume":"75","author":"DG Johnston","year":"1983","unstructured":"Johnston DG  et al. (1983) Hyperprolactinemia. Long-term effects of bromocriptine. Am J Med. 75: 868\u2013874","journal-title":"Am J Med."},{"key":"BFncpendmet0160_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(84)90480-X","volume":"2","author":"DG Johnston","year":"1984","unstructured":"Johnston DG  et al. (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerized tomography. Lancet 2: 187\u2013192","journal-title":"Lancet"},{"key":"BFncpendmet0160_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2265.1982.tb03175.x","volume":"16","author":"T Bergh","year":"1982","unstructured":"Bergh T  et al. (1982) Menstrual function and prolactin levels after long-term bromocriptine treatment of prolactinaemic amenorrhea. Clin Endocrinol 16: 587\u2013593","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0160_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0015-0282(16)47593-X","volume":"41","author":"WS Maxson","year":"1984","unstructured":"Maxson WS  et al. (1984) Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil Steril 41: 218\u2013223","journal-title":"Fertil Steril"},{"key":"BFncpendmet0160_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1530\/acta.0.1040139","volume":"104","author":"A Zarate","year":"1983","unstructured":"Zarate A  et al. (1983) Follow-up of patients with prolactinoma after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol 104: 139\u2013142","journal-title":"Acta Endocrinol"},{"key":"BFncpendmet0160_CR35","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1210\/jcem-60-4-764","volume":"60","author":"P Moriondo","year":"1985","unstructured":"Moriondo P  et al. (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60: 764\u2013772","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR36","first-page":"817","volume-title":"Prolactin. Basic and Clinical Correlates","author":"W Winkelmann","year":"1985","unstructured":"Winkelmann W  et al. (1985) Persisting normoprolactinemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas. In Prolactin. Basic and Clinical Correlates, 817\u2013822 (Eds MacLeod RM  et al.) Padova, Italy: Liviana Press"},{"key":"BFncpendmet0160_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2265.1987.tb01163.x","volume":"27","author":"C Wang","year":"1987","unstructured":"Wang C  et al. (1987) Long-term treatment of hyperprolactinemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol 27: 363\u2013371","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0160_CR38","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","volume":"87","author":"VQ Passos","year":"2002","unstructured":"Passos VQ  et al. (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87: 3578\u20133582","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","volume":"63","author":"M Biswas","year":"2005","unstructured":"Biswas M  et al. (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol 63: 26\u201331","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0160_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","volume":"34","author":"JW van't Verlaat","year":"1991","unstructured":"van't Verlaat JW and Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size. Clin Endocrinol 34: 175\u2013178","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0160_CR41","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1210\/jcem-53-3-480","volume":"53","author":"MO Thorner","year":"1981","unstructured":"Thorner MO  et al. (1981) Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 53: 480\u2013483","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","volume":"100","author":"ML Vance","year":"1984","unstructured":"Vance ML  et al. (1984) Drugs five years later. Bromocriptine. Ann Intern Med 100: 78\u201391","journal-title":"Ann Intern Med"},{"key":"BFncpendmet0160_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/A:1011412028660","volume":"3","author":"JJ Orrego","year":"2000","unstructured":"Orrego JJ  et al. (2000) Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 3: 189\u2013192","journal-title":"Pituitary"},{"key":"BFncpendmet0160_CR44","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1210\/jcem-58-6-1179","volume":"58","author":"AM Landolt","year":"1984","unstructured":"Landolt AM and Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58: 1179\u20131183","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR45","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/BF01727477","volume":"65","author":"P Krupp","year":"1987","unstructured":"Krupp P and Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65: 823\u2013827","journal-title":"Klin Wochenschr"},{"key":"BFncpendmet0160_CR46","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.1982.03320360039028","volume":"247","author":"I Turkalj","year":"1982","unstructured":"Turkalj I  et al. (1982) Surveillance of bromocriptine in pregnancy. JAMA 247: 1589\u20131591","journal-title":"JAMA"},{"key":"BFncpendmet0160_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJM198608283150903","volume":"315","author":"A Klibanski","year":"1986","unstructured":"Klibanski A and Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315: 542\u2013546","journal-title":"N Engl J Med"},{"key":"BFncpendmet0160_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","volume":"39","author":"J Webster","year":"1993","unstructured":"Webster J  et al. (1993) The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol 39: 323\u2013329","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0160_CR49","first-page":"2338","volume":"81","author":"BMK Biller","year":"1996","unstructured":"Biller BMK  et al. (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81: 2338\u20132343","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR50","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao A  et al. (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82: 3574\u20133579","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR51","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/BF03343561","volume":"22","author":"S Cannav\u00f2","year":"1999","unstructured":"Cannav\u00f2 S  et al. (1999) Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 22: 306\u2013309","journal-title":"J Endocrinol Invest"},{"key":"BFncpendmet0160_CR52","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/oxfordjournals.humrep.a136149","volume":"10","author":"C Ferrari","year":"1995","unstructured":"Ferrari C  et al. (1995) Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum Reprod 10: 1647\u20131652","journal-title":"Hum Reprod"},{"key":"BFncpendmet0160_CR53","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"Colao A  et al. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349: 2023\u20132033","journal-title":"N Engl J Med"},{"key":"BFncpendmet0160_CR54","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1530\/acta.0.1260489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari C  et al. (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 126: 589\u2013594","journal-title":"Acta Endocrinol"},{"key":"BFncpendmet0160_CR55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/BF03348016","volume":"20","author":"M Muratori","year":"1997","unstructured":"Muratori M  et al. (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20: 537\u2013546","journal-title":"J Endocrinol Invest"},{"key":"BFncpendmet0160_CR56","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF03343573","volume":"22","author":"S Cannav\u00f2","year":"1999","unstructured":"Cannav\u00f2 S  et al. (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenomas. J Endocrinol Invest 22: 354\u2013359","journal-title":"J Endocrinol Invest"},{"key":"BFncpendmet0160_CR57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","volume":"63","author":"M Biswas","year":"2005","unstructured":"Biswas M  et al. (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol 63: 26\u201331","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0160_CR58","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0890-6238(96)00063-9","volume":"10","author":"E Robert","year":"1996","unstructured":"Robert E  et al. (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10: 333\u2013337","journal-title":"Reprod Toxicol"},{"key":"BFncpendmet0160_CR59","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0890-6238(02)00055-2","volume":"16","author":"E Ricci","year":"2002","unstructured":"Ricci E  et al. (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16: 791\u2013793","journal-title":"Reprod Toxicol"},{"key":"BFncpendmet0160_CR60","first-page":"3053","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"Pinzone JJ  et al. (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85: 3053\u20133057","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR61","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03349742","volume":"18","author":"M Berezin","year":"1995","unstructured":"Berezin M  et al. (1995) Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest 18: 436\u2013441","journal-title":"J Endocrinol Invest"},{"key":"BFncpendmet0160_CR62","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1445-5994.1997.tb02196.x","volume":"27","author":"JP Walsh","year":"1997","unstructured":"Walsh JP and Pullan PT (1997) Hyperprolactinaemia in males: a heterogeneous disorder. Austr NZ J Med 27: 385\u2013390","journal-title":"Austr NZ J Med"},{"key":"BFncpendmet0160_CR63","first-page":"37","volume":"27","author":"M Somma","year":"1981","unstructured":"Somma M  et al. (1981) Prolactinoma in the male. Preoperative evaluation of 40 patients [French]. Neurochirurgie 27: 37\u201339","journal-title":"Neurochirurgie"},{"key":"BFncpendmet0160_CR64","first-page":"1782","volume":"111","author":"T Eversmann","year":"1981","unstructured":"Eversmann T  et al. (1981) Hyperprolactinemia in the male: clinical aspects and therapy [German]. Schweiz Med Wochenschr 111: 1782\u20131789","journal-title":"Schweiz Med Wochenschr"},{"key":"BFncpendmet0160_CR65","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0140-6736(82)91094-7","volume":"2","author":"RF Spark","year":"1982","unstructured":"Spark RF  et al. (1982) Hyperprolactinaemia in males with and without pituitary macroadenomas. Lancet 2: 129\u2013132","journal-title":"Lancet"},{"key":"BFncpendmet0160_CR66","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.0954-6820.1985.tb01642.x","volume":"217","author":"AL Hulting","year":"1985","unstructured":"Hulting AL  et al. (1985) Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Med Scand 217: 101\u2013109","journal-title":"Acta Med Scand"},{"key":"BFncpendmet0160_CR67","first-page":"241","volume":"13","author":"F Grisoli","year":"1980","unstructured":"Grisoli F  et al. (1980) Prolactin secreting adenoma in 22 men. Surg Neurol 13: 241\u2013247","journal-title":"Surg Neurol"},{"key":"BFncpendmet0160_CR68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11102-005-5111-4","volume":"8","author":"A Chattopadhyay","year":"2005","unstructured":"Chattopadhyay A  et al. (2005) Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 8: 147\u2013154","journal-title":"Pituitary"},{"key":"BFncpendmet0160_CR69","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","volume":"83","author":"C Di Somma","year":"1998","unstructured":"Di Somma C  et al. (1998) Bone markers and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83: 807\u2013813","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR70","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1530\/eje.0.1350548","volume":"135","author":"A Colao","year":"1996","unstructured":"Colao A  et al. (1996) Chronic treatment with CV 205-52 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 135: 548\u2013552","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0160_CR71","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1530\/eje.0.1380286","volume":"138","author":"M De Rosa","year":"1998","unstructured":"De Rosa M  et al. (1998) Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 138: 286\u2013293","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0160_CR72","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A  et al. (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89: 1704\u20131711","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR73","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","volume":"64","author":"M De Rosa","year":"2006","unstructured":"De Rosa M  et al. (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol 64: 307\u2013313","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0160_CR74","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1210\/jc.2003-030852","volume":"89","author":"M De Rosa","year":"2004","unstructured":"De Rosa M  et al. (2004). Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 89: 621\u2013625","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR75","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.4065\/73.11.1046","volume":"73","author":"RD Calle-Rodrigue","year":"1998","unstructured":"Calle-Rodrigue RD  et al. (1998) Prolactinomas in male and female patients: a comparative clinico-pathology study. Mayo Clin Proc 73: 1046\u20131052","journal-title":"Mayo Clin Proc"},{"key":"BFncpendmet0160_CR76","first-page":"2102","volume":"82","author":"E Delgrange","year":"1997","unstructured":"Delgrange E  et al. (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82: 2102\u20132107","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0160_CR77","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1056\/NEJM198003273021313","volume":"302","author":"D Parkes","year":"1980","unstructured":"Parkes D (1980) Side effects of bromocriptine. N Engl J Med 302: 749\u2013750","journal-title":"N Engl J Med"},{"key":"BFncpendmet0160_CR78","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","volume":"14","author":"J Webster","year":"1996","unstructured":"Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14: 228\u2013238","journal-title":"Drug Saf"}],"container-title":["Nature Clinical Practice Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0160","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:49:11Z","timestamp":1684439351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpendmet0160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["BFncpendmet0160"],"URL":"https:\/\/doi.org\/10.1038\/ncpendmet0160","relation":{},"ISSN":["1745-8366","1745-8374"],"issn-type":[{"value":"1745-8366","type":"print"},{"value":"1745-8374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}